- Processing Solutions
- White Papers
- Tech Portals
- Buyer's Guide
NORFOLK, Va. — Pfizer Inc. has won a patent-infringement case against Teva Pharmaceutical Industries Ltd., according to Bloomberg.
The decision by a U.S. federal court prevents Israel-based Teva from marketing a generic version of the anti-impotence drug Viagra until 2019.
“Protecting the intellectual property rights of our innovative core is critical,” Amy Schulman, Pfizer’s general counsel, said in a statement. “Friday’s court decision acknowledges Teva’s clear violation of our patent rights.”